Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|!WLOCK|?&LOCK|mhHgV%

Sartorius Stedim Earnings: Guidance Reaffirmed Despite Slowdown in New Equipment Sales

Sartorius Stedim Biotech reported its second-quarter 2025 results, where the revenue miss was offset by an underlying EBITDA beat against company-compiled consensus. Sales increased 8.4% in constant currency, while underlying EBITDA increased by 18.7%. Shares are trading 10% lower intraday.

Sponsor Center